Want to see JP:4884 full AI Analyst Report?
Top Page
Kringle Pharma, Inc.
(4884)
Select Model
Select Model
Rating:52Neutral
Price Target:
¥650.00
▲(71.50% Upside)
Action:Reiterated
Date:10/15/26
The score is held back mainly by weak financial performance (heavy losses, declining recent revenue, and ongoing cash burn) and limited valuation support (negative P/E, no dividend data). These are partially offset by strong technical momentum, with the stock trading above key moving averages and positive MACD.
Positive Factors
Debt-Free Balance Sheet
The absence of reported debt reduces fixed financial obligations and refinancing exposure, which is valuable for a biotechnology company facing uncertain development timelines. This gives management more flexibility to allocate available resources toward research and operations without servicing a large borrowing burden.
Negative Factors
Persistent Structural Losses
Persistent operating and net losses indicate that the current business model has not yet reached economic sustainability. Deeply negative margins can restrict reinvestment, weaken shareholder value, and leave future growth dependent on successful commercialization or continued access to external funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-Free Balance Sheet
The absence of reported debt reduces fixed financial obligations and refinancing exposure, which is valuable for a biotechnology company facing uncertain development timelines. This gives management more flexibility to allocate available resources toward research and operations without servicing a large borrowing burden.
Read all positive factors
Kringle Pharma, Inc. (4884) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥5.10B
Dividend YieldN/A
Average Volume (3M)334.68K
Price to Earnings (P/E)―
Beta (1Y)0.28
Revenue Growth372.42%
EPS Growth22.75%
CountryJP
Employees17
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-110.74
Shares Outstanding8,593,200
10 Day Avg. Volume579,030
30 Day Avg. Volume334,680
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)2.41
Price to Sales (P/S)43.77
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)286
Revenue Forecast (FY)¥4.07B
Kringle Pharma, Inc. Business Overview & Revenue Model
Company Description
Kringle Pharma, Inc. specializes in the innovation, production, and distribution of hepatocyte growth factor (HGF) protein-based therapeutics aimed at regenerative medicine. The company's cutting-edge HGF solutions are designed to address serious ...
Kringle Pharma, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
20
Very Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 341.47M | 72.22M | 80.04M | 69.25M | 391.83M | 289.76M |
| Gross Profit | 234.20M | 72.22M | 0.00 | 0.00 | 303.42M | 218.16M |
| EBITDA | -806.45M | -909.45M | -817.88M | -888.76M | -426.17M | -357.88M |
| Net Income | -808.44M | -916.25M | -756.45M | -854.15M | -331.83M | -301.17M |
Balance Sheet | ||||||
| Total Assets | 2.00B | 2.08B | 2.76B | 2.62B | 3.21B | 2.64B |
| Cash, Cash Equivalents and Short-Term Investments | 1.70B | 1.62B | 2.31B | 2.14B | 2.76B | 2.14B |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 744.51M | 770.11M | 648.92M | 596.95M | 419.50M | 129.48M |
| Stockholders Equity | 1.25B | 1.31B | 2.11B | 2.02B | 2.79B | 2.51B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 0.00 | -661.17M | -689.10M | 15.80M | -560.92M |
| Operating Cash Flow | -755.78M | -755.78M | -661.17M | -689.10M | 15.80M | -560.92M |
| Investing Cash Flow | -154.01M | -154.01M | -121.36M | -120.88M | -254.38M | 0.00 |
| Financing Cash Flow | 84.14M | 84.14M | 838.23M | 69.16M | 603.11M | 595.90M |
Kringle Pharma, Inc. Technical Analysis
Positive
379.00
Price Trends
487.42
Positive
407.73
Positive
412.93
Positive
Market Momentum
43.21
Positive
58.30
Neutral
30.60
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4884, the sentiment is Positive. The current price of 379 is below the 20-day moving average (MA) of 573.50, below the 50-day MA of 487.42, and below the 200-day MA of 412.93, indicating a bullish trend. The MACD of 43.21 indicates Positive momentum. The RSI at 58.30 is Neutral, neither overbought nor oversold. The STOCH value of 30.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4884.
Kringle Pharma, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | ¥5.10B | -5.62 | ― | ― | 372.42% | 22.75% | |
48 Neutral | ¥140.80B | -39.19 | -7.17% | ― | 0.62% | 27.66% | |
46 Neutral | ¥3.75B | -2.89 | ― | ― | 1135.58% | 2.37% | |
45 Neutral | ¥1.52B | -0.59 | ― | ― | ― | 20.94% | |
43 Neutral | ¥2.18B | -1.13 | ― | ― | -62.54% | 10.12% | |
42 Neutral | ¥6.64B | -5.80 | -33.61% | ― | 74.24% | -7.78% |
* General Sector Average
JP:4884
Kringle Pharma, Inc.
610.00
153.00
33.48%
JP:4587
Peptidream
1,072.50
-597.00
-35.76%
JP:4571
NanoCarrier Co., Ltd.
82.00
-84.00
-50.60%
JP:4591
Ribomic, Inc.
65.00
-30.00
-31.58%
JP:4598
Delta-Fly Pharma, Inc.
75.00
-403.00
-84.31%
JP:4881
FunPep Company Limited
42.00
-57.00
-57.58%
Kringle Pharma, Inc. Corporate Events
Kringle Pharma Seeks U.S. Phase 3 Trial for Spinal Cord Injury Drug
Sep 24, 2026
Kringle Pharma has submitted an Investigational New Drug application to the U.S. FDA seeking to initiate a Phase 3 clinical trial of oremepermin alfa, a recombinant human hepatocyte growth factor, for the treatment of acute spinal cord injury in t...
Kringle Pharma Boosts Sales but Warns of Deeper Full-Year Losses
Aug 10, 2026
Kringle Pharma reported a sharp rise in net sales to ¥323 million for the nine months ended June 30, 2026, up more than fivefold year on year, but continued to post operating and net losses, with a nine-month loss of ¥631 million and a b...
Kringle Pharma Launches Additional Phase 3 Trial of Oremepermin Alfa in Acute Spinal Cord Injury
Jul 24, 2026
Kringle Pharma has launched an additional Phase 3 trial in Japan to evaluate oremepermin alfa, a recombinant human hepatocyte growth factor, in patients with acute cervical spinal cord injury. The multicenter, open-label study will enroll 10 adult...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.